Commerzbank Ag reaffirmed their buy rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a research note published on Friday, July 28th.
Several other analysts have also recently weighed in on the stock. TheStreet cut shares of Qiagen N.V. from a b- rating to a c rating in a research note on Monday, April 24th. Zacks Investment Research cut shares of Qiagen N.V. from a hold rating to a sell rating in a research note on Wednesday, April 5th. Deutsche Bank AG reissued a buy rating on shares of Qiagen N.V. in a research note on Tuesday, May 2nd. Barclays PLC reissued a buy rating and issued a $33.00 price target on shares of Qiagen N.V. in a research note on Monday, May 15th. Finally, Morgan Stanley reissued an overweight rating and issued a $37.00 price target (up previously from $36.00) on shares of Qiagen N.V. in a research note on Monday, July 10th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $33.17.
Shares of Qiagen N.V. (QGEN) traded down 0.85% during mid-day trading on Friday, reaching $31.36. 603,125 shares of the company’s stock traded hands. The stock has a market capitalization of $7.16 billion, a PE ratio of 95.90 and a beta of 1.14. Qiagen N.V. has a 12-month low of $24.86 and a 12-month high of $35.26. The company’s 50-day moving average price is $33.30 and its 200-day moving average price is $31.23.
Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The business had revenue of $349 million during the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter in the prior year, the company posted $0.24 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Analysts anticipate that Qiagen N.V. will post $1.23 earnings per share for the current year.
WARNING: “Commerzbank Ag Reaffirms “Buy” Rating for Qiagen N.V. (QGEN)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2017/08/15/qiagen-n-v-qgen-given-buy-rating-at-commerzbank-ag-updated-updated.html.
Several institutional investors have recently modified their holdings of the company. FNY Managed Accounts LLC bought a new position in shares of Qiagen N.V. during the first quarter valued at approximately $103,000. Acrospire Investment Management LLC raised its position in shares of Qiagen N.V. by 11.7% in the second quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after buying an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Qiagen N.V. during the first quarter valued at approximately $114,000. Quadrant Capital Group LLC raised its position in shares of Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock valued at $154,000 after buying an additional 4,421 shares in the last quarter. Finally, Rehmann Capital Advisory Group bought a new position in shares of Qiagen N.V. during the first quarter valued at approximately $207,000. Hedge funds and other institutional investors own 60.07% of the company’s stock.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
